J Cancer 2019; 10(16):3608-3617. doi:10.7150/jca.31832

Research Paper

AC138128.1 an Intronic lncRNA originating from ERCC1 Implies a Potential Application in Lung Cancer Treatment

Mingyang Xiao1, Su Cui2, Liang Zhang3, Tao Yu1, Guopei Zhang1, Qianye Zhang1, Liuli Li1, Yuan Cai1, Cuihong Jin1, Jinghua Yang1, Shengwen Wu1, Xiaobo Lu1✉

1. Dept. of Toxicology, School of Public Health, China Medical University, Shenyang, P.R. China
2. Dept. of Thoracic Surgery Ward 2, The first Hospital of China Medical University, Shenyang, P.R. China
3. Dept. of Thoracic Surgery, Liaoning Cancer Hospital & Institute, Shenyang, P.R. China

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Xiao M, Cui S, Zhang L, Yu T, Zhang G, Zhang Q, Li L, Cai Y, Jin C, Yang J, Wu S, Lu X. AC138128.1 an Intronic lncRNA originating from ERCC1 Implies a Potential Application in Lung Cancer Treatment. J Cancer 2019; 10(16):3608-3617. doi:10.7150/jca.31832. Available from http://www.jcancer.org/v10p3608.htm

File import instruction

Abstract

Lung cancer is one of the most devastating tumors with a high incidence and mortality worldwide. Polymorphisms and expression of ERCC1 commonly predicted the occurrence and prognosis of lung cancer. However, few studies have focused on long non-coding RNAs related to ERCC1 though some studies reminded the importance of its post-transcriptional regulation. In the present study, an intronic lncRNA AC138128.1 originated from ERCC1 was firstly identified in microarray chip and database, and its possibility as a novel biomarker to predict lung cancer treatment was further discussed. Firstly, the qRT-PCR data showed that AC138128.1 expression was much lower in lung cancer comparing with its para-cancer tissues, which further analyzed by ROC curve. Similarly, the difference was also verified in 16HBE, A549 and LK2 cells. Then AC138128.1 expression was found to have an increasing trend in a dose or time-dependent manner after cisplatin treatment. Finally, the subcellular distribution of AC138128.1 reminded that AC138128.1 was mainly expressed in the nucleus. Interestingly a positive relationship between AC138128.1 and ERCC1 expression was only found in cancer tissues, which reminded AC138128.1 may be involved in the regulation of ERCC1. Therefore, as a preliminary exploration of the lncRNA originated from ERCC1, the present study suggested AC138128.1 is of potential value in predicting platinum analogue benefit in lung cancer.

Keywords: AC138128.1, intronic lncRNA, ERCC1, lung cancer, platinum analogue